AILBRY - Article Search
Serach over 250 million academic articles from all areas of study
Results for 'Matthew D. Hellmann'
:
Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026
Publication Year: 2017
DOI: https://doi.org/10.1158/1538-7445.am2017-ct082
Abstract:
Add to Library
Authors:
Solange Peters
Ben Creelan
Matthew D. Hellmann
Mark A. Socinski
Martin Reck
Prabhu Bhagavatheeswaran
Han Chang
William J. Geese
Luis Paz‐Ares
David P. Carbone
Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568
Publication Year: 2018
DOI: https://doi.org/10.1158/1538-7445.am2018-ct078
Abstract:
Add to Library
Authors:
Suresh S. Ramalingam
Matthew D. Hellmann
Mark M. Awad
Hossein Borghaei
Justin F. Gainor
Julie R. Brahmer
David R. Spigel
Martin Reck
Kenneth J. O’Byrne
Luis Paz‐Ares
Kim E. Zerba
Xuemei Li
William J. Geese
George Green
Brian Lestini
Joseph D. Szustakowski
Han Chang
Neal Ready
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
Publication Year: 2018
DOI: https://doi.org/10.1200/jco.2018.79.0006
Abstract:
Add to Library
Authors:
Kathryn C. Arbour
Laura Mezquita
Niamh M. Long
Hira Rizvi
Édouard Auclin
Ai Ni
Gala Martínez-Bernal
Roberto Ferrara
W. Victoria Lai
Lizza E.L. Hendriks
Joshua K. Sabari
Caroline Caramella
Andrew J. Plodkowski
Darragh Halpenny
Jamie E. Chaft
David Planchard
Gregory J. Riely
Benjamin Besse
Matthew D. Hellmann
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Publication Year: 2018
DOI: https://doi.org/10.1016/j.ccell.2018.04.001
Abstract:
Add to Library
Authors:
Matthew D. Hellmann
Margaret K. Callahan
Mark M. Awad
Emiliano Calvo
Paolo A. Ascierto
Akin Atmaca
Naiyer A. Rizvi
Fred R. Hirsch
Giovanni Selvaggi
Joseph D. Szustakowski
Ariella Sasson
Ryan Golhar
Patrik Vitazka
Chang Han
William J. Geese
Scott Antonia
Abstract CT125: A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad <i>de novo</i> anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer
Publication Year: 2018
DOI: https://doi.org/10.1158/1538-7445.am2018-ct125
Abstract:
Add to Library
Authors:
Patrick A. Ott
Ramaswamy Govindan
Aung Naing
Terence W. Friedlander
Kim Margolin
W. Marston Linehan
Nina Bhardwaj
Matthew D. Hellmann
Lakshmi Srinivasan
Joel Greshock
Melissa A. Moles
Richard B. Gaynor
Matthew J. Goldstein
Siwen Hu‐Lieskovan
Abstract CT289: Pembrolizumab plus lenvatinib vs docetaxel in patients with previously treated metastatic non-small-cell lung cancer (NSCLC) and PD after platinum-doublet chemotherapy and immunotherapy: Phase 3, randomized, open-label LEAP-008 trial
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.am2020-ct289
Abstract:
Add to Library
Authors:
Natasha B. Leighl
Rina Hui
Delvys Rodríguez‐Abreu
Makoto Nishio
Matthew D. Hellmann
Chooi Lee
Xuan Deng
Debra Kush
Hossein Borghaei
Justin F. Gainor
Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227
Publication Year: 2018
DOI: https://doi.org/10.1158/1538-7445.am2018-ct077
Abstract:
Add to Library
Authors:
Matthew D. Hellmann
Tudor–Eliade Ciuleanu
Adam Płużański
Jong Seok Lee
Gregory A. Otterson
Clarisse Audigier-Valette
Elisa Minenza
Helena Linardou
Sjaak Burgers
Pamela Salman
Hossein Borghaei
Suresh S. Ramalingam
Julie R. Brahmer
Martin Reck
Kenneth J. O’Byrne
William J. Geese
George Green
Han Chang
Joseph D. Szustakowski
Prabhu Bhagavatheeswaran
Diane Healey
Yali Fu
Faith E. Nathan
Luis Paz‐Ares
Abstract CT079: Neoadjuvant PD-1 blockade in resectable lung cancer
Publication Year: 2018
DOI: https://doi.org/10.1158/1538-7445.am2018-ct079
Abstract:
Add to Library
Authors:
Patrick M. Forde
Jamie E. Chaft
Kellie N. Smith
Valsamo Anagnostou
Tricia R. Cottrell
Matthew D. Hellmann
Marianna Zahurak
Stephen C. Yang
David R. Jones
Stephen Broderick
Richard J. Battafarano
Moises J. Velez
Natasha Rekhtman
Zachary T. Olah
Jarushka Naidoo
Kristen A. Marrone
Franco Verde
Haidan Guo
Jiajia Zhang
Justina X. Caushi
Hok Yee Chan
John-William Sidhom
Robert B. Scharpf
J. W. White
Edward Gabrielson
Hao Wang
Gary L. Rosner
Valerie W. Rusch
Jedd D. Wolchok
Taha Merghoub
Janis M. Taube
Victor E. Velculescu
Suzanne L. Topalian
Julie R. Brahmer
Drew M. Pardoll
Franciscans and preaching : every miracle from the beginning of the world came about through words
Publication Year: 2012
DOI: DOI not
available
Abstract:
Add to Library
Authors:
Abstract 5671: Alignment of TMB measured on clinical samples: Phase IIB of the Friends of Cancer Research TMB Harmonization Project
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.am2020-5671
Abstract:
Add to Library
Authors:
Diana M. Merino
Laura M. Yee
Lisa M. McShane
P. Mickey Williams
Tomas Vilimas
Rajesh Patidar
J. Carl Barrett
Shu‐Jen Chen
Jen‐Hao Cheng
Jeffrey M. Conroy
Dinesh Cyanam
Kenneth R. Eyring
David Fabrizio
Vincent Funari
Elizabeth P. Garcia
Sean T. Glenn
Christopher D. Gocke
Vikas Gupta
Lisa Haley
Matthew D. Hellmann
Laurel A. Keefer
Lauryn Keeler
Brett W. C. Kennedy
Alexander J. Lazar
Laura E. MacConaill
Kristen L. Meier
Arnaud Papin
Naiyer A. Rizvi
Ethan Sokol
Phillip Stafford
John F. Thompson
Warren Tom
Victor Weigman
Mingchao Xie
Chen Zhao
Mark Stewart
Jeff Allen
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Publication Year: 2018
DOI: https://doi.org/10.1016/j.ccell.2018.03.018
Abstract:
Add to Library
Authors:
Matthew D. Hellmann
Tavi Nathanson
Hira Rizvi
Ben Creelan
Francisco Sánchez-Vega
Arun Ahuja
Ai Ni
Jacki B. Novik
Levi Mangarin
Mohsen Abu-Akeel
Cailian Liu
Jennifer L. Sauter
Natasha Rekhtman
Eliza Chang
Margaret K. Callahan
Jamie E. Chaft
Martin H. Voss
Megan Tenet
Xuemei Li
Kelly L. Covello
Andrea Renninger
Patrik Vitazka
William J. Geese
Hossein Borghaei
Charles M. Rudin
Scott Antonia
Charles Swanton
Jeff Hammerbacher
Taha Merghoub
Nicholas McGranahan
Alexandra Snyder
Jedd D. Wolchok
Abstract CT041: Identification of gene signatures associated with response in a Phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy
Publication Year: 2019
DOI: https://doi.org/10.1158/1538-7445.am2019-ct041
Abstract:
Add to Library
Authors:
Peter Ordentlich
Lei Wang
David Tamang
Amy Sullivan
Sally E. Church
Dan Rozelle
Michael L. Meyers
Suresh S. Ramalingam
Matthew D. Hellmann
Abstract 2299: Misclassification of clonal hematopoietic mutations as tumor-derived confound accurate ctDNA-response assessment in patients with metastatic non-small-cell lung cancer: analyses from the phase 3 MYSTIC trial
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.am2023-2299
Abstract:
Add to Library
Authors:
Chris Abbosh
Michael Kuziora
Daniel Stetson
Zhongwu Lai
Yashaswi Shrestha
Paul Labrousse
Xiaojin Shi
Helen Mann
Diana Merino Vega
Matthew D. Hellmann
Solange Peters
J. Carl Barrett
Darren Hodgson
Foreign Aid, Institutions, and Governance in Sub‐Saharan Africa
Publication Year: 2004
DOI: https://doi.org/10.1086/380592
Abstract:
Add to Library
Authors:
Deborah Bräutigam
Stephen Knack
Abstract CT169: A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.am2020-ct169
Abstract:
Add to Library
Authors:
Fadi Braiteh
Patricia LoRusso
Ani Sarkis Balmanoukian
S.J. Klempner
D. Ross Camidge
Matthew D. Hellmann
Michael S. Gordon
Johanna C. Bendell
Lars Müeller
Rachel Lubong Sabado
Patrick Twomey
Leila Delamarre
Jack Y.J. Huang
Mahesh Yadav
Jingbin Zhang
Patrick J. McDonald
Felicitas Müller
Evelyna Derhovanessian
Özlem Türeci
Uğur Şahin
Lillian L. Siu
Found 200 results in 0.298 seconds
What is Boolean Searches
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE . You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Example Search
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"